Listed

Actinium Pharmaceuticals, Inc.

ATNMNYSECIK 1388320HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$35.0mRevenue, Q2 FY2026, three months to 2026-06-30$35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 7, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$35.0mRevenue, Q2 FY2026, three months to 2026-06-30$35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figureNo year-earlier figure to compare
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin78.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $27.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Revenue: $35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figureNo year-earlier figure to compare
  • Net margin79.7%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $27.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Revenue: $35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figureNo year-earlier figure to compare
  • Diluted EPS$0.89Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figureSign changed from a year earlier
  • Free cash flow−$5.7mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Capital expenditure: $478.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Report this figureNo year-earlier figure to compare

Last eight quarters

Full statements
Revenue$35.0mOperating margin 78.8%
Diluted EPS$0.89, Q2 FY2026
Free cash flow−$5.7m, Q2 FY2026
Actinium Pharmaceuticals, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)0.1Revenue, Q3 FY2025, three months to 2025-09-30$90.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)35.0Revenue, Q2 FY2026, three months to 2026-06-30$35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(6324.4%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Revenue: $90.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue not reported)78.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $27.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Revenue: $35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(5701.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Revenue: $90.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue not reported)79.7%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $27.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Revenue: $35.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Diluted EPS$ per share(0.37)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported (Diluted EPS not reported)(0.51)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(0.22)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure(0.16)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110979.Report this figurenot reported (Diluted EPS not reported)(0.18)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure0.89Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001213900-26-086769.Report this figure
Free cash flow$m(12.0)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$12.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001213900-25-110979. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001213900-25-110979. Derived: 9-month figure less the 6-month figure.Report this figure(5.8)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001213900-26-036504. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(5.9)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$5.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001213900-26-053980.Report this figure(5.7)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Capital expenditure: $478.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001213900-26-086769. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$90.0kOperating margin −40274.4%
Diluted EPS−$1.09, FY2025
Free cash flow−$24.7m, FY2025
Actinium Pharmaceuticals, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1.1Revenue, FY2021, twelve months to 2021-12-31$1.1m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-31, accession 0001213900-23-025597.Report this figure1.0Revenue, FY2022, twelve months to 2022-12-31$1.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-29, accession 0001213900-24-028038.Report this figure0.1Revenue, FY2023, twelve months to 2023-12-31$81.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figurenot reported (Revenue not reported)0.1Revenue, FY2025, twelve months to 2025-12-31$90.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)
Operating margin%(2182.2%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$25.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-31, accession 0001213900-23-025597.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-31, accession 0001213900-23-025597.Report this figure(3311.1%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$34.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-29, accession 0001213900-24-028038.Revenue: $1.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-29, accession 0001213900-24-028038.Report this figure(64098.8%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$51.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001213900-25-026371.Revenue: $81.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figurenot reported (Revenue not reported)(40274.4%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$36.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036504.Revenue: $90.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure
Net margin%(2165.6%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$24.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-31, accession 0001213900-23-025597.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-31, accession 0001213900-23-025597.Report this figure(3205.5%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$33.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-29, accession 0001213900-24-028038.Revenue: $1.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-29, accession 0001213900-24-028038.Report this figure(60269.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$48.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001213900-25-026371.Revenue: $81.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figurenot reported (Revenue not reported)(37652.2%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$33.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036504.Revenue: $90.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure
Diluted EPS$ per share(1.20)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-31, accession 0001213900-23-025597.Report this figure(1.37)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-29, accession 0001213900-24-028038.Report this figure(1.83)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure(1.27)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure(1.09)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure
Free cash flow$m(21.0)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$20.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-31, accession 0001213900-23-025597.Capital expenditure: $133.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-31, accession 0001213900-23-025597.Report this figure8.3Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-29, accession 0001213900-24-028038.Capital expenditure: $366.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-29, accession 0001213900-24-028038.Report this figure(47.5)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$47.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001213900-25-026371.Capital expenditure: $153.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001213900-25-026371.Report this figure(33.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$33.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036504.Capital expenditure: $11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure(24.7)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$24.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036504.Capital expenditure: $104.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001213900-26-036504.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Actinium Pharmaceuticals, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.2m1,238,302Reduced−17,214
COMPASS FINANCIAL MANAGEMENT LLC2026-06-30$588.2k600,230Not compared
MILLENNIUM MANAGEMENT LLC2026-06-30$504.3k514,580Reduced−50,020
BlackRock, Inc.2026-06-30$388.0k395,896Added+24,686
RENAISSANCE TECHNOLOGIES LLC2026-06-30$372.9k380,491Reduced−91,109
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$318.6k324,945Reduced−11,128
TWO SIGMA INVESTMENTS, LP2026-06-30$254.0k259,179Reduced−77,989
GAGNON SECURITIES LLC2026-06-30$178.5k182,142Reduced−19,158
VANGUARD FIDUCIARY TRUST CO2026-06-30$158.3k161,526Added+1,261
STATE STREET CORP2026-06-30$119.8k122,215Reduced−4,000

Recent filings

All 496 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Actinium Pharmaceuticals, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1611:42 ETDEF 14AProxy statementPeriod 2026-11-250001213900-26-110022
2026-10-1521:05 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-109884
2026-08-1421:00 ET8-K3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-090232
2026-08-0721:00 ET10-QQuarterly reportPeriod 2026-06-300001213900-26-086769
2026-06-1821:00 ET8-K8.01 Other events0001213900-26-070193
2026-05-2921:10 ET8-K3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-062935
2026-05-0821:00 ET10-QQuarterly reportPeriod 2026-03-310001213900-26-053980
2026-03-3021:39 ET10-KAnnual reportPeriod 2025-12-310001213900-26-036504
2026-03-2621:00 ET8-K/A5.07 Shareholder vote results0001213900-26-034807
2026-02-1322:00 ET8-K5.02 Departure or appointment of officers or directors0001213900-26-016559

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 30, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1388320
Tickers
ATNM
Exchange
NYSE
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Cactus Ventures, Inc. (to 2013-03-29)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.